ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025
Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Chronic Spontaneous Urticaria in Finland - A Nationwide Registry Study on Epidemiology and Treatment Patterns in Secondary Care.Acta dermato-venereologica · 2026Article
- Comment on 'Family quality-of-life burden in chronic spontaneous urticaria: A multicentre study'.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Knowledge of chronic spontaneous urticaria management among Italian general practitioners: Baseline findings from the BRIDGE study.The World Allergy Organization journal · 2026Article
- Psychological Wellbeing of Patients with Chronic Spontaneous Urticaria and Its Relation to Their Overall Health-Related Quality of Life.Clinical, cosmetic and investigational dermatology · 2026Article
- Type 2 Inflammation in Chronic Spontaneous Urticaria: Presentation, Role, and Management.Journal of inflammation research · 2026Review
- Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- The burden of chronic spontaneous urticaria in Europe: Call for action.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- The societal costs associated with patients with chronic spontaneous urticaria (CSU) in Italy.Global & regional health technology assessmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough chronic spontaneous urticaria (CSU) is a common form of chronic urticaria (CU), its impact on overall disease burden and treatment patterns in real-world settings requires further understanding.
objectivesTo assess prevalence, treatment patterns, disease profile and burden in patients with CSU in five European countries (EU5: France, Germany, Italy, Spain and the United Kingdom [UK]).
methodsData were from the 2020 EU5 National Health and Wellness Survey (NHWS). Age- and sex-adjusted prevalence of diagnosed CSU was estimated for the overall EU5 and by country. Sociodemographic, health characteristics, treatment history and dermatology-specific quality of life were described for the CSU cohort. Patient-reported outcomes, including the Short Form 12-item Survey (SF-12v2) mental (MCS), physical component (PCS) summary scores; SF-6D; EQ-5D; General Anxiety Disorder-7 (GAD-7); Patient Health Questionnaire-9 (PHQ-9); Work Productivity and Activity Impairment (WPAI) and healthcare resource use (HRU), were summarized for the CSU cohort, overall and by country and descriptively compared to the full NHWS sample.
resultsOf 62,319 respondents, 794 patients were diagnosed with CU. Among these, 519 had CSU. Weighted prevalence of CSU in EU5 was 0.92%. Roughly half of the CSU cohort was treated with prescription and/or over-the-counter medication. Among the CSU cohort, 36.7% of patients experienced a very large to extremely large disease impact (Dermatology Life Quality Index [DLQI] > 10); most had poorly controlled disease (71.6%). Mean MCS, PCS, SF-6D and EQ-5D scores were worse for CSU versus the full NHWS sample. A higher proportion of the CSU cohort, versus the full NHWS sample, had GAD-7 and PHQ-9 scores of ≥5. Mild-severe anxiety, depression and WPAI scores were highest in the UK. HRU was higher in the CSU cohort than in the full NHWS sample.
conclusionsCSU negatively impacts patients' lives. Yet, many patients remain inadequately treated and uncontrolled. These results highlight a need for comprehensive care approaches to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.